22nd Century Group (XXII) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Jun, 2026Executive summary
Special Meeting scheduled for August 5, 2026, to vote on five key proposals, including a reverse stock split, inducement warrants, and new equity offerings.
Record date for voting eligibility is June 15, 2026, with 345,124 shares of common stock entitled to vote.
Voting can be done online, by phone, mail, or in person, with quorum set at one-third of outstanding shares.
Voting matters and shareholder proposals
Proposal 1: Approve a reverse stock split at a ratio between 1-for-2 and 1-for-200 to comply with Nasdaq listing rules.
Proposal 2: Approve issuance of 3,019,586 inducement warrants and shares issuable upon exercise, potentially dilutive.
Proposal 3: Approve a potential $20 million offering of new convertible preferred stock and warrants.
Proposal 4: Approve a potential $10 million offering of common stock and warrants.
Proposal 5: Approve adjournment of the meeting to solicit additional proxies if needed.
Board of directors and corporate governance
Board has discretionary authority to implement or abandon the reverse split within 24 months of approval.
Board recommends voting in favor of all proposals.
Stockholder proposals for the 2027 Annual Meeting must be received by February 1, 2027.
Latest events from 22nd Century Group
- Net revenues fell 29.9% as focus shifted to higher-margin branded products amid going concern risks.XXII
Q2 2026 - Special Meeting seeks approval for reverse split, new warrants, and equity offerings to maintain Nasdaq listing.XXII
Proxy filing - Registering 3M+ shares for resale, with dilution and going concern risks amid FDA-authorized focus.XXII
Registration filing - Q1 2026 revenue was $4.1M, up sequentially but down year-over-year, with ongoing liquidity concerns.XXII
Q1 2026 - Proxy seeks director election, executive pay approval, auditor ratification, and highlights growth strategy.XXII
Proxy filing - Shelf registration enables up to $250M in offerings; $1.84M at-the-market sale supports VLN growth.XXII
Registration filing - Net loss narrowed, debt eliminated, and VLN® distribution expanded for growth.XXII
Q4 2025 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference - Revenue grew, losses narrowed, but going concern risk persists as VLN rebranding continues.XXII
Q2 2024